Newsfeeds - Spark Newswire

1 minute read

JMP Securities Maintains Market Outperform on eFFECTOR Therapeutics, Lowers Price Target to $8

January 25, 7:38 AM

JMP Securities analyst Reni Benjamin maintains eFFECTOR Therapeutics (NASDAQ:EFTR) with a Market Outperform and lowers the price target from $33 to $8.

EFTR

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

December 29, 2:15 PM

BFRI

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For November 9, 2021

By Benzinga Insights

November 9, 11:05 AM

ADCT

1 minute read

Stifel Upgrades eFFECTOR Therapeutics to Buy, Announces $20 Price Target

By Benzinga Newsdesk

November 9, 5:08 AM

Stifel analyst Benjamin Burnett upgrades eFFECTOR Therapeutics (NASDAQ:EFTR) from Hold to Buy and announces $20 price target.

EFTR

1 minute read

eFFECTOR Therapeutics Q3 EPS $0.42 Up From $(5.29) YoY, Sales $427.00K Down From $574.00K YoY

By Benzinga Newsdesk

November 8, 8:07 AM

eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly earnings of $0.42 per share. This is a 107.94 percent increase over losses of $(5.29) per share from the same period last year. The company reported $427.00

EFTR

10 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 12, 2021

By Benzinga Insights

October 12, 10:48 AM

Upgrades

ABNB

1 minute read

Credit Suisse Initiates Coverage On eFFECTOR Therapeutics with Outperform Rating, Announces Price Target of $20

By Benzinga Newsdesk

October 12, 6:15 AM

Credit Suisse analyst Judah Frommer initiates coverage on eFFECTOR Therapeutics (NASDAQ:EFTR) with a Outperform rating and announces Price Target of $20.

EFTR

3 minute read